Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 48.00 | |
5 mg | In stock | $ 113.00 | |
10 mg | In stock | $ 178.00 | |
25 mg | In stock | $ 369.00 | |
50 mg | In stock | $ 588.00 | |
100 mg | In stock | $ 926.00 |
Description | GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U2OS cancer cells, positioning it as a potential investigational tool in cancer research [1] [2]. |
In vitro | GP-82996, at concentrations of 5 and 10 μM applied for 24 hours, causes a G1 phase arrest and an increase in the G0-G1/S ratio in U2OS (p16 negative) and MRC-5 (p16 positive) cells, while reducing the hyperphosphorylation of pRb without affecting CDK4 levels in these cell lines. In U2OS cells, a 48-hour exposure to 10μM of GP-82996 results in apoptosis in 83% of the population. Additionally, GP-82996 inhibits the proliferation of A549, H358, SKLU-1, H23, and PC14 cells, with IC50 values around 4-7 μM after 72 hours of treatment. The compound also induces G1 arrest in A549 and H23 cells at concentrations of 3, 5, and 10 μM over 48 hours and enhances the sensitivity of KRAS mutation-bearing lung cancer cells (A549, SKLU-1, H23) to Paclitaxel with varied concentrations (1, 3, 5, 10 μM) over 72 hours. A combination of GP-82996 (10 μM) and Paclitaxel (3 nM) over 72 hours notably increases apoptosis in A549 and H23 cells. |
In vivo | GP-82996 (30 mg/kg, i.p. for 29 days) demonstrated a reduction in final tumor volume compared to the vehicle control in mouse xenograft models [1]. Utilizing female BALB/c nu/nu mice, weighing 19-21 g, with HCT116 tumors measuring 100 mm^3, the compound was administered intraperitoneally (i.p.) at a dosage of 30 mg/kg every 12 hours over a period of 29 days, resulting in noticeably smaller final tumor volumes in comparison to those observed in the vehicle control group [1]. |
Synonyms | Cdk4/6 Inhibitor IV, CINK4 |
Molecular Weight | 456.58 |
Formula | C27H32N6O |
CAS No. | 359886-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 27mg/mL (59.1mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GP-82996 359886-84-3 Cell Cycle/Checkpoint CDK GP82996 CINK-4 Cdk4/6 Inhibitor IV CINK4 GP 82996 CINK 4 inhibitor inhibit